🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

RecruitingPhase 2, Phase 3Ages 18 Years - 99 YearsAllColumbia University
NCT07079735 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Patients who are \>18 years of age who have received a heart transplant and have not started their CMV prophylaxis regimen will be included. Exclusion Criteria: History of or suspected CMV disease within 6 months prior is excluded.
💊

What it tests

  • Letermovir
  • Valganciclovir
📍

Where

2 sites
NYP-Weill Cornell
New York, United States
Columbia University/NYP Milstein Hospital
New York, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy